APP and Alzheimer disease: Ginsenoside F1 can reduce the level of phosphorylated CREB, increase the level of BDNF in the hippocampal cortex, reduce Aβ plaques, and improve the memory function of APP/PS1 transgenic AD mice (Han et al., 2019).